Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 2
1982 12
1983 3
1984 2
1985 4
1986 9
1987 13
1988 7
1989 18
1990 23
1991 18
1992 15
1993 11
1994 18
1995 10
1996 16
1997 18
1998 14
1999 10
2000 10
2001 14
2002 7
2003 17
2004 4
2005 8
2006 9
2007 9
2008 6
2009 11
2010 8
2011 5
2012 14
2013 8
2014 8
2015 8
2016 5
2017 6
2018 3
2019 2
2020 5
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

373 results
Results by year
Filters applied: . Clear all
Page 1
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G; STAR*D Investigators Group. Rush AJ, et al. Control Clin Trials. 2004 Feb;25(1):119-42. doi: 10.1016/s0197-2456(03)00112-0. Control Clin Trials. 2004. PMID: 15061154 Clinical Trial.
After receiving citalopram (level 1), participants without sufficient symptomatic benefit are eligible for randomization to level 2 treatments, which entail four switch options (sertraline, bupropion, venlafaxine, cognitive therapy) and three citalopram augment options (bupropion …
After receiving citalopram (level 1), participants without sufficient symptomatic benefit are eligible for randomization to level 2 treatmen …
Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.
Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, Liu Y, Fang Y, da Silva T, Zhang Y, Fang L, Wang X, Xie P. Zhou X, et al. J Clin Psychiatry. 2015 Apr;76(4):e487-98. doi: 10.4088/JCP.14r09204. J Clin Psychiatry. 2015. PMID: 25919841 Clinical Trial.
STUDY SELECTION: Randomized controlled trials comparing 11 augmentation agents (aripiprazole, bupropion, buspirone, lamotrigine, lithium, methylphenidate, olanzapine, pindolol, quetiapine, risperidone, and thyroid hormone) with each other and with placebo for adult treatme …
STUDY SELECTION: Randomized controlled trials comparing 11 augmentation agents (aripiprazole, bupropion, buspirone, lamotrigine, lith …
Comparison of the Efficacy of Buspirone and Placebo in Childhood Functional Abdominal Pain: A Randomized Clinical Trial.
Badihian N, Yaghini O, Badihian S, Shahsanai A, Saneian H. Badihian N, et al. Am J Gastroenterol. 2020 May;115(5):756-765. doi: 10.14309/ajg.0000000000000589. Am J Gastroenterol. 2020. PMID: 32221160 Clinical Trial.
We randomly assigned patients to receive buspirone or placebo for 4 weeks, with the adjusted dosage for age. ...Further studies, with the higher doses of buspirone and longer follow-ups are recommended....
We randomly assigned patients to receive buspirone or placebo for 4 weeks, with the adjusted dosage for age. ...Further studies, with …
A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
Talaei A, Hosseini FF, Aghili Z, Akhondzadeh S, Asadpour E, Mehramiz NJ, Forouzanfar F. Talaei A, et al. Can J Physiol Pharmacol. 2020 Apr;98(4):236-242. doi: 10.1139/cjpp-2019-0381. Epub 2020 Mar 31. Can J Physiol Pharmacol. 2020. PMID: 32228235 Clinical Trial.
Some studies use augmentative treatment by antipsychotics, glutamatergic, lithium, buspirone, and others agents to improve the therapeutic response. In this study, we aimed to evaluate the efficacy and tolerability of aripiprazole and quetiapine as augmentative treatments …
Some studies use augmentative treatment by antipsychotics, glutamatergic, lithium, buspirone, and others agents to improve the therap …
Pharmacokinetics of a prototype formulation of sublingual testosterone and a buspirone tablet, versus an advanced combination tablet of testosterone and buspirone in healthy premenopausal women.
van Rooij K, de Leede L, Frijlink HW, Bloemers J, Poels S, Koppeschaar H, Olivier B, Tuiten A. van Rooij K, et al. Drugs R D. 2014 Jun;14(2):125-32. doi: 10.1007/s40268-014-0047-7. Drugs R D. 2014. PMID: 24849043 Free PMC article. Clinical Trial.
Thirteen women received testosterone via the sublingual route followed 2.5 hours later by a buspirone tablet, versus a single combination tablet swallowed at once. ...We also demonstrated that there was adequate absorption of buspirone (>80 % relative to the conv …
Thirteen women received testosterone via the sublingual route followed 2.5 hours later by a buspirone tablet, versus a single combina …
Buspirone decreases susceptibility to hypocapnic central sleep apnea in chronic SCI patients.
Maresh S, Prowting J, Vaughan S, Kruppe E, Alsabri B, Yarandi H, Badr MS, Sankari A. Maresh S, et al. J Appl Physiol (1985). 2020 Oct 1;129(4):675-682. doi: 10.1152/japplphysiol.00435.2020. Epub 2020 Aug 20. J Appl Physiol (1985). 2020. PMID: 32816639 Free PMC article. Clinical Trial.
We hypothesized that Buspirone and Trazodone would decrease the propensity to hypocapnic CSA during sleep. ...CG was significantly decreased on Buspirone compared with placebo (1.8 0.4 vs. 4.0 2.0 L/(mmHgmin), P = 0.025) but not on Trazodone compared with placebo (2 …
We hypothesized that Buspirone and Trazodone would decrease the propensity to hypocapnic CSA during sleep. ...CG was significantly de …
Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial.
Davari-Ashtiani R, Shahrbabaki ME, Razjouyan K, Amini H, Mazhabdar H. Davari-Ashtiani R, et al. Child Psychiatry Hum Dev. 2010 Dec;41(6):641-8. doi: 10.1007/s10578-010-0193-2. Child Psychiatry Hum Dev. 2010. PMID: 20517641 Clinical Trial.
A total of 34 children with ADHD as defined by DSM-IV-TR were randomized to buspirone or methylphenidate dosed on weight-adjusted basis at buspirone (0.5 mg/kg/day) and methylphenidate (0.3-1 mg/kg/day) for a 6-week double-blind clinical trial. ...These preliminary …
A total of 34 children with ADHD as defined by DSM-IV-TR were randomized to buspirone or methylphenidate dosed on weight-adjusted bas …
A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder.
Ross CA, Matas M. Ross CA, et al. Can J Psychiatry. 1987 Jun;32(5):351-5. doi: 10.1177/070674378703200505. Can J Psychiatry. 1987. PMID: 3308052 Clinical Trial.
In double-blind trials with hundreds of patients, buspirone has proven to be as effective an anxiolytic as the benzodiazepines. ...Maximum doses were 40 mg of diazepam or buspirone or eight placebo tablets a day. There were no significant differences in outcome betw …
In double-blind trials with hundreds of patients, buspirone has proven to be as effective an anxiolytic as the benzodiazepines. ...Ma …
A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism.
Ghanizadeh A, Ayoobzadehshirazi A. Ghanizadeh A, et al. Pediatr Neurol. 2015 Jan;52(1):77-81. doi: 10.1016/j.pediatrneurol.2014.09.017. Epub 2014 Oct 5. Pediatr Neurol. 2015. PMID: 25451017 Clinical Trial.
RESULTS: Eighteen patients in the placebo group and 16 patients in the buspirone group completed this trial. The mean dose of buspirone was 6.7 (SD 2.7) mg/day. ...There were no serious adverse effects. The most common adverse effects in the buspirone group w …
RESULTS: Eighteen patients in the placebo group and 16 patients in the buspirone group completed this trial. The mean dose of busp
Comparison of ketanserin, buspirone and propranolol on arousal, pupil size and autonomic function in healthy volunteers.
Koudas V, Nikolaou A, Hourdaki E, Giakoumaki SG, Roussos P, Bitsios P. Koudas V, et al. Psychopharmacology (Berl). 2009 Jul;205(1):1-9. doi: 10.1007/s00213-009-1508-5. Epub 2009 Mar 14. Psychopharmacology (Berl). 2009. PMID: 19288084 Clinical Trial.
OBJECTIVES: We examined the profile of the 5HT-2/alpha1/H1 antagonist ketanserin, the 5HT1a agonist buspirone and the beta adrenoceptor antagonist propranolol on pupillary and other measures of arousal. MATERIALS AND METHODS: Ketanserin (20 mg), buspirone (10 mg) an …
OBJECTIVES: We examined the profile of the 5HT-2/alpha1/H1 antagonist ketanserin, the 5HT1a agonist buspirone and the beta adrenocept …
373 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page